Abstract
In order to develop novel central acting drugs, the modulation of intracellular Ca2+ dynamics must be considered as an essential factor, since following excessive Ca2+ influx to neuronal cells, abnormal intracellular Ca2+ concentrations induce several types of mental and neurological disorders. This paper introduces some voltage sensitive Ca2+ channel blockers (Ca antagonists) which may be useful in the treatment of neuro-psychiatric diseases, such as manic depressive insanity, schizophrenia, ischemia-induced neuronal death and/or amnesia. The pharmacological actions of Ca antagonists may be explained by these possible direct central actions due to permeation of the blood-brain barrier. Furthermore, the central pharmacological actions of Ca antagonists may be explained by these possible direct central actions due to permeation of the blood-brain barrier. Furthermore, the central pharmacological properties of newly synthesized GABA-peptides, which influence cytosolic Ca2+ levels and bind to GABAA receptor, are also discussed as a novel class of psychiatric drugs. Copyright © 1998 John Wiley & Sons, Ltd.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Human Psychopharmacology: Clinical and Experimental
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
